Sera Prognostics, a women's health company, reported a net loss of $8.1 million for Q1 2024, an improvement from the $10.6 million loss in Q1 2023. The company's operating expenses decreased by $2.3 million year-on-year, with research and development expenses down by $420,000, selling and marketing expenses reduced by $1.6 million, and general and administrative expenses lowered by $276,000. Despite these reductions, Sera Prognostics has not generated significant revenue, with Q1 2024 revenue at zero compared to $100,000 in Q1 2023. The company's focus remains on its PreTRM test, a blood-based biomarker test for predicting preterm birth risk, and other pipeline products. Clinical trials have shown the PreTRM test's efficacy, and the company is preparing for the publication of its PRIME study results. Sera Prognostics is actively working...Show More

Sera Prognostics, a women's health company, reported a net loss of $8.1 million for Q1 2024, an improvement from the $10.6 million loss in Q1 2023. The company's operating expenses decreased by $2.3 million year-on-year, with research and development expenses down by $420,000, selling and marketing expenses reduced by $1.6 million, and general and administrative expenses lowered by $276,000. Despite these reductions, Sera Prognostics has not generated significant revenue, with Q1 2024 revenue at zero compared to $100,000 in Q1 2023. The company's focus remains on its PreTRM test, a blood-based biomarker test for predicting preterm birth risk, and other pipeline products. Clinical trials have shown the PreTRM test's efficacy, and the company is preparing for the publication of its PRIME study results. Sera Prognostics is actively working to reduce operating expenses and extend its cash runway into 2027. The company continues to seek market adoption of the PreTRM test and is developing additional tests, including one for more accurate delivery date estimation. Sera Prognostics is headquartered in Salt Lake City, Utah, and operates a CLIA-certified laboratory. The company's future plans include negotiating contracts with private and governmental payers, expanding clinical utility data, and validating whole-blood collection technologies to potentially lower costs and increase market penetration.